Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J I Weitz

Showing results (51-60 of 136) with videos related to

Pageof 14
Sort By:
Journal of Thrombosis and Haemostasis : JTH|July 8, 2015
Medical device-induced thrombosis: what causes it and how can we prevent it?I H Jaffer, J C Fredenburgh, J Hirsh, et al.
Advances in Experimental Medicine and Biology|January 1, 1997
Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexesD L Becker, J C Fredenburgh, A R Stafford, et al.
The Journal of Biological Chemistry|February 26, 1999
Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor IID L Becker, J C Fredenburgh, A R Stafford, et al.
Blood|August 15, 1992
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparinG Agnelli, C Renga, J I Weitz, et al.
Circulation|September 16, 1998
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study resultsS S Anand, S Yusuf, J Pogue, et al.
The Journal of Laboratory and Clinical Medicine|January 9, 1998
The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearanceL Manson, J I Weitz, T J Podor, et al.
Blood|August 15, 1989
Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptideB Kudryk, M Gidlund, A Rohoza, et al.
Thrombosis and Haemostasis|April 4, 2014
Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding modelsN Vaezzadeh, R Ni, P Y Kim, et al.
Archives of Internal Medicine|February 15, 2001
Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparinS M Bates, J I Weitz, M Johnston, et al.
Thrombosis and Haemostasis|February 1, 1993
The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethyleneF D Rubens, J I Weitz, J L Brash, et al.
Pageof 14

Showing results (51-60 of 136) with videos related to

Sort By:
Pageof 14
Journal of Thrombosis and Haemostasis : JTH|July 8, 2015
Medical device-induced thrombosis: what causes it and how can we prevent it?I H Jaffer, J C Fredenburgh, J Hirsh, et al.
Advances in Experimental Medicine and Biology|January 1, 1997
Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexesD L Becker, J C Fredenburgh, A R Stafford, et al.
The Journal of Biological Chemistry|February 26, 1999
Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor IID L Becker, J C Fredenburgh, A R Stafford, et al.
Blood|August 15, 1992
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparinG Agnelli, C Renga, J I Weitz, et al.
Circulation|September 16, 1998
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study resultsS S Anand, S Yusuf, J Pogue, et al.
The Journal of Laboratory and Clinical Medicine|January 9, 1998
The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearanceL Manson, J I Weitz, T J Podor, et al.
Blood|August 15, 1989
Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptideB Kudryk, M Gidlund, A Rohoza, et al.
Thrombosis and Haemostasis|April 4, 2014
Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding modelsN Vaezzadeh, R Ni, P Y Kim, et al.
Archives of Internal Medicine|February 15, 2001
Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparinS M Bates, J I Weitz, M Johnston, et al.
Thrombosis and Haemostasis|February 1, 1993
The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethyleneF D Rubens, J I Weitz, J L Brash, et al.
Pageof 14